A composition is hereby provided. The present composition comprises one or more micro-sized particles in the form of a core-shell. The core comprises an active agent and ingredients subject to pH-triggered dissolution, enzymatically-degradable ingredients and/or water-insoluble ingredients. The shell comprises one or more ingredients being characterized as enteric ingredients, enzymatically-degradable, and as water-insoluble ingredients. The particles may be dispersed in a liquid or other non-dry composition.

A therapeutic method of treatment of diabetes mellitus, particularly diabetes which acquires insulin resistance, including administering a therapeutically effective amount of Chinese herbal medicine to a subject in need. The Chinese herbal medicine is the decocting extract including the mixture of raw oyster shell powder, raw Os Draconis, Haematitum (Hematite), Magnetitum (Magnetite), radix Achyranthis Bidentatae (Achyranthes bidentata), rhizoma Dioscoreae (Dioscoreae Rhizoma), radix Paeoniae Rubra (Paeoniae Radix Rubra), radix Rehmanniae (Rehmannia), and semen Platycladi (Platycladi Semen).

A therapeutic method of treatment of diabetes mellitus, particularly diabetes which acquires insulin resistance, including administering a therapeutically effective amount of Chinese herbal medicine to a subject in need. The Chinese herbal medicine is the decocting extract including the mixture of raw oyster shell powder, raw Os Draconis, Haematitum (Hematite), Magnetitum (Magnetite), radix Achyranthis Bidentatae (Achyranthes bidentata), rhizoma Dioscoreae (Dioscoreae Rhizoma), radix Paeoniae Rubra (Paeoniae Radix Rubra), radix Rehmanniae (Rehmannia), and semen Platycladi (Platycladi Semen).

A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.

A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.

A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.

A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.

The present application discloses a solid beverage for conditioning blood stasis constitution. The solid beverage comprises the following components in parts by weight: 21-55 parts of hawthorn, 9-33 parts of peach seed, 9-33 parts of gingko, 5-21 parts of platycodon grandiflorus, 9-33 parts of dried tangerine peel, 0.5-4 parts of cinnamon, 9-33 parts of the root of kudzu vine, 2-21 parts of dahurian angelica, 10-29 parts of dextrin, 7-25 parts of maltodextrin, 8-26 parts of soluble starch and 0.05-0.2 parts of aspartame. The solid beverage of the present application is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, and has certain effects on the improvement of blood stasis constitution, and the production process thereof is suitable for industrial mass production.

The present application discloses a solid beverage for conditioning blood stasis constitution. The solid beverage comprises the following components in parts by weight: 21-55 parts of hawthorn, 9-33 parts of peach seed, 9-33 parts of gingko, 5-21 parts of platycodon grandiflorus, 9-33 parts of dried tangerine peel, 0.5-4 parts of cinnamon, 9-33 parts of the root of kudzu vine, 2-21 parts of dahurian angelica, 10-29 parts of dextrin, 7-25 parts of maltodextrin, 8-26 parts of soluble starch and 0.05-0.2 parts of aspartame. The solid beverage of the present application is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, and has certain effects on the improvement of blood stasis constitution, and the production process thereof is suitable for industrial mass production.

The present application discloses a solid beverage for conditioning blood stasis constitution. The solid beverage comprises the following components in parts by weight: 21-55 parts of hawthorn, 9-33 parts of peach seed, 9-33 parts of gingko, 5-21 parts of platycodon grandiflorus, 9-33 parts of dried tangerine peel, 0.5-4 parts of cinnamon, 9-33 parts of the root of kudzu vine, 2-21 parts of dahurian angelica, 10-29 parts of dextrin, 7-25 parts of maltodextrin, 8-26 parts of soluble starch and 0.05-0.2 parts of aspartame. The solid beverage of the present application is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, and has certain effects on the improvement of blood stasis constitution, and the production process thereof is suitable for industrial mass production.